Empatica Announces Integration of Mobilise-D Mobility Outcomes, Advancing Toward Unified Solution for Clinical Professionals
June 18 2024 - 8:04AM
Business Wire
Mobilise-D Advanced Mobility Analytics will be implemented
within Empatica Health Monitoring Platform
Empatica, a pioneer in digital biomarker development and patient
monitoring driven by AI, today announced a partnership with
Mobilise-D, an initiative funded by the Innovative Medicines
Initiative (IMI) and EFPIA partners, and coordinated by Newcastle
University. This collaboration will integrate Mobilise-D’s
validated Digital Mobility Outcomes (DMOs) into Empatica’s Health
Monitoring Platform, bringing it one step closer to becoming a
single, unified destination for implementing digital endpoints in
clinical care and research.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240618632289/en/
All Digital Mobility Outcomes developed
by the Mobilise-D consortium will be accessible through the
Empatica Health Monitoring Platform (Photo: Business Wire)
“We are proud to be the first non-consortium member to implement
the Mobilise-D consortium’s groundbreaking development and
validation work,” said Simone Tognetti, Empatica’s CTO and
Co-founder. “This means our Platform can now provide 25 new,
validated outcomes for COPD, Parkinson’s, Multiple Sclerosis, and
Proximal femoral fracture. The demand for high-quality,
purpose-specific measures is immense, and Empatica is ready to
support the dissemination of the consortium’s innovative work
within the industry.”
The project was launched to innovate ways to better assess
people’s mobility in daily life using digital measures and wearable
sensors, aiding therapeutic development, clinical practice, and
precision medicine. With this partnership, all Mobilise-D DMOs can
be measured with Empatica’s EmbracePlus wearable and accessed
through the Empatica Health Monitoring Platform, consolidating
advanced mobility analytics with Empatica’s robust technology.
Lynn Rochester, Professor at Newcastle University and Mobilise-D
co-lead, said, “A major barrier to the implementation of digital
outcomes in clinical trials is the availability of systems that can
deliver accurate and reliable data in a timely and seamless manner.
We are delighted that Empatica have chosen to integrate the
Mobilise-D advanced mobility analytics, addressing this barrier and
moving digital outcome assessment closer to a sustainable solution
that drives much-needed innovation and harmonization in clinical
trials.”
Providing Mobilise-D’s algorithms alongside Empatica’s service
and technology makes it easier for pharma companies to include them
in their studies, reducing patient and site burden. Mobilise-D is
the first public program to systematically combine device
considerations, analytical and clinical validation, and patient and
regulatory engagement to generate reliable evidence for digital
measures. The critical support from key pharmaceutical companies in
the pipeline development leading to the dissemination of these
endpoints highlights the collaborative effort required to drive
innovation in the industry. Utilizing the algorithms in
interventional clinical trial settings is a key step toward the
regulatory approval of digital endpoints in clinical drug
development.
Visit Empatica’s website to learn more about its full digital
measure offering and how the Empatica Health Monitoring Platform
can facilitate clinical care and research.
Empatica
Empatica Inc is a pioneer in continuous, unobtrusive remote
health monitoring driven by AI. Empatica's FDA-cleared platform and
technology are used by thousands of institutional partners for
research purposes, in studies examining stress, sleep, epilepsy,
migraine, depression, addiction, and other conditions. Its flagship
medical wearable, EmbracePlus, has been developed with key partners
including HHS, USAMRDC, and the NASA-funded TRISH.
Mobilise-D
Mobilise-D is a consortium funded under the EU Innovative
Medicines Initiative and EFPIA partners comprised of experts from
22 academic institutions, 12 industry partners from pharmaceutical,
technology, and clinical research organisations, and people with
diverse health conditions and mobility impairments. The primary
objective of Mobilise-D was to develop a novel method to accurately
and reliability assess change in one’s mobility in the real-world
environment using digital technologies, including a single
body-worn device. The project focused on conditions which affect
mobility, including COPD, Parkinson’s disease, multiple sclerosis,
hip fracture recovery, and congestive heart failure.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240618632289/en/
Marianna Xenophontos mx@empatica.com